Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 1, 2026Diabetes and Vascular Disease ResearchOpen Access

Upregulated miR-143-3p expression distinguished diabetic cardiomyopathy from diabetes and promoted high glucose-induced cardiomyocyte injury in vitro by targeting ERBB3.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

This work aimed to verify the value of miR-143-3p in diabetic cardiomyopathy.

Does miR-143-3p serve as a diagnostic biomarker for diabetic cardiomyopathy and regulate high glucose-induced cardiomyocyte injury?

Population

Subjects with DCM, subjects with DM, and healthy individuals, alongside in vitro AC16 cardiomyocytes

Comparison

DCM vs DM vs healthy individuals

Design

Clinical biomarker and in vitro mechanistic study

Key result

Upregulated miR-143-3p expression distinguished diabetic cardiomyopathy from diabetes and promoted high glucose-induced cardiomyocyte injury in vitro by targeting ERBB3.

Authors

ZZZhengnan ZhangSWSuyun WANGLZLiping Zhu

Discussion

Loading...

Member takes

Overview

miR-143-3p may aid DCM diagnosis; hypothesis-generating for ERBB3 targeting pending prospective trials.

Study Design

Type

Observational

Structured PICO

Does miR-143-3p serve as a diagnostic biomarker for diabetic cardiomyopathy and regulate high glucose-induced cardiomyocyte injury?

P
Population
Subjects with diabetes mellitus (DM), subjects with diabetic cardiomyopathy (DCM), healthy individuals, and in vitro high glucose (HG)-stimulated cardiomyocyte (AC16) model.
E
Exposure
miR-143-3p inhibition (in vitro)
C
Comparator
Healthy individuals and DM patients without DCM (clinical); uninhibited/control cells (in vitro)
O
Outcome
Diagnostic value of miR-143-3p for DCM and its effect on high glucose-induced cardiomyocyte injury (proliferation, apoptosis, inflammation, oxidative stress, myocardial enzymes)surrogate

miR-143-3p shows potential as a diagnostic biomarker for diabetic cardiomyopathy and its inhibition protects against high glucose-induced cardiomyocyte injury via ERBB3.

Cite This Study

Zhang et al. (2026) conducted an observational in Diabetic cardiomyopathy. miR-143-3p expression vs. Healthy individuals and diabetes patients without cardiomyopathy was evaluated on Diagnostic value for diabetic cardiomyopathy and in vitro cardiomyocyte injury. Upregulated miR-143-3p expression distinguished diabetic cardiomyopathy from diabetes and promoted high glucose-induced cardiomyocyte injury in vitro by targeting ERBB3.

synapsesocial.com/papers/6a6f56d435aa2c282ce0b748https://doi.org/10.1177/14791641261454501
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Circulating exosomal mir-16-2-3p is associated with coronary microvascular dysfunction in diabetes through regulating the fatty acid degradation of endothelial cells2024 · 14 citations
  2. 2MicroRNA: unveiling novel mechanistic and theranostic pathways in diabetic cardiomyopathy2025 · 7 citations
  3. 3MiR-20a-5p overexpression prevented diabetic cardiomyopathy via inhibition of cardiomyocyte apoptosis, hypertrophy, fibrosis and JNK/NF-κB signalling pathway2021 · 36 citations
  4. 4miR-200a-3p overexpression alleviates diabetic cardiomyopathy injury in mice by regulating autophagy through the FOXO3/Mst1/Sirt3/AMPK axis2023 · 22 citations
  5. 5MicroRNA-494 Regulates High Glucose-Induced Cardiomyocyte Apoptosis and Autophagy by PI3K/AKT/mTOR Signalling Pathway2023 · 32 citations